Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
暂无分享,去创建一个
Tanja Fehm | Carsten Denkert | Peter A Fasching | Mahdi Rezai | Christine Solbach | Bernd Gerber | M. Rezai | P. Fasching | T. Fehm | C. Denkert | R. Kreienberg | H. Tesch | S. Loibl | M. Untch | V. Nekljudova | J. Blohmer | G. von Minckwitz | J. Huober | C. Jackisch | C. Hanusch | H. Eidtmann | B. Müller | C. Solbach | B. Gerber | Rolf Kreienberg | Gunter von Minckwitz | Hans Tesch | Sibylle Loibl | Michael Untch | Jens-Uwe Blohmer | Jens Huober | Valentina Nekljudova | I. Schrader | Holger Eidtmann | M. Hauschild | Christian Jackisch | Berit Maria Müller | H. Eggemann | Claus Hanusch | Holm Eggemann | Iris Schrader | Kornelia Kittel | Georg Kunz | Maik Hauschild | K. Kittel | G. Kunz
[1] N. Breslow,et al. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. , 1981 .
[2] Arlene Chan,et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Fasching,et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials , 2010, Breast Cancer Research and Treatment.
[4] E. Van Cutsem,et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[6] S. Loibl,et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.
[7] Xian Zhou,et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Fehm,et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] J. Blohmer,et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Dewhirst,et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. , 2000, Journal of the National Cancer Institute.
[12] C. Denkert,et al. Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study , 2010, Breast Cancer Research and Treatment.
[13] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[14] James A Young,et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. , 2012, The New England journal of medicine.
[15] P. Fasching,et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Peter A Fasching,et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Baselga,et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.
[18] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[20] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Simpson,et al. Statistical methods in cancer research , 2001, Journal of surgical oncology.
[22] J. Thigpen. RIBBON-1: Randomized, Double-blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer , 2011 .
[23] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] V. Miller,et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Barbara L. Smith,et al. Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery? , 2011, Annals of Surgical Oncology.